Taking people in ChinaNo phase
Compares two routes for heat ablation of early peripheral lung cancer
Tests heat ablation through the chest wall or airway in adults with early lung cancer.
Key facts
- Who runs it
- Shanghai Chest Hospital
- Where
- Shanghai, ChinaSee the site
- Trial code
- Registry title
- Transthoracic vs Transbronchial Radiofrequency Ablation for Lung Cancer
- Status
- Recruiting
- People taking part
- 110 people, planned
- Started
- 4 Jan 2024
- Expected to end
- Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ablation
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early-stage (stage IA) lung cancer near the edge of the lung who are not having surgery. It compares two ways of doing ablation.
- Age
- Older than 18 years.
- Sex
- All sexes can join.
- Disease stage
- Primary peripheral lung cancer confirmed by pathology, clinical stage T1N0M0, stage IA (new and multiple primary cancers after an operation are included). The tumour must be reachable by CT-guided and bronchoscopy-guided ablation.
- Earlier treatment
- The person is judged unsuitable for surgery or refuses surgery, and agrees to ablation as the first treatment. Blood-thinning or anti-platelet drugs (except dabigatran, rivaroxaban and other new oral anticoagulants) must be stopped 5 to 7 days before ablation.
Main reasons for not taking part
- Platelets below 50×109/L, or severe bleeding or clotting problems that cannot be corrected soon
- Severe pulmonary fibrosis or pulmonary arterial hypertension
- Severe liver, kidney, heart, lung or brain failure that cannot be improved soon
- ECOG score above 2, or other tumours with wide spread and expected survival under 6 months
- Implanted electronic device such as a pacemaker or defibrillator, or pregnancy or planned pregnancy
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age greater than 18 years
- Primary peripheral lung cancer diagnosed by pathology and pre-procedure staging examination suggesting clinical stage T1N0M0, stage IA (including postoperative new and multiple primary)
- The proposed ablation lesion was evaluated for feasibility of CT and bronchoscopy-guided ablation treatment
- Consent to initial ablation therapy is given after assessment of unsuitability for surgery or refusal of surgery and signed informed consent form
Who cannot take part
- Patients with severe pulmonary fibrosis and pulmonary arterial hypertension
- Infectious and radioactive inflammation around the lesion, skin infection at the puncture site that is not well controlled, systemic infection, high fever >38.5°C
- Patients with severe hepatic, renal, cardiac, pulmonary and cerebral insufficiency, severe anaemia, dehydration and serious disorders of nutritional metabolism that cannot be corrected or improved in the short term
- Those with poorly controlled malignant pleural effusions
- Any other condition that the investigator considers inappropriate for participation in this study
- Patients with platelets <50×109/L, severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term
- Anticoagulation therapy and/or anti-platelet drugs (except dabigatran, rivaroxaban and other new oral anticoagulants) have not been discontinued more than 5~7d before ablation
- Eastern Cooperative Oncology Group (ECOG) score >2
- Combination of other tumours with extensive metastases and an expected survival of <6 months
- Patients with episodic psychosis
- Patients with implanted electronic devices (e.g. pacemakers or defibrillators)
- Pregnant women, or patients with a pregnancy planned during the study period
- Have participated or are participating in other clinical studies within the last 30 days
Where in China
- Shanghai Chest HospitalShanghai, ChinaContact: Jiayuan Sun, PhDTaking people
About the trial
What the trial wants to find out
The aim of this study is to investigate the efficacy and safety of transthoracic versus transbronchial ablation in the treatment of early stage peripheral lung cancer.
The 2 groups in the trial
- Transthoracic ablationExisting treatment, for comparison
Treatment: ablation
- Transbronchial ablationTreatment being tested
Treatment: ablation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Transthoracic Versus Transbronchial Radiofrequency Ablation for Peripheral Lung Cancer Staging IA: a Prospective, Randomized Controlled Trial
- Plain-language title
- Compares two routes for heat ablation of early peripheral lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 April 2026